Assembly Biosciences, Inc.

Assembly Biosciences develops therapeutic candidates for viral diseases. They have several products in clinical trials: ABI-5366 for recurrent genital herpes, ABI-1179 for recurrent genital herpes, and ABI-6250 for hepatitis delta virus. They also develop ABI-4334 for hepatitis B virus and other treatments targeting transplant-related herpesviruses and HBV/HDV. The company has partnerships with Gilead Sciences and BeiGene.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

21.2 USD

Potential

-100%

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	0.8